PRODUCT FILTER
Categories
Type
Type

Elnitine
OTC

Elnitine is a combination of magnesium gluconate and calcium glycerophosphate. Magnesium represents the second most common intracellar cation in the human organism and plays a fundamental role in cell physiology. Calcium is the main mineral element in the human body, calcium ensures the rigidity and solidity of the skeleton and the hardness of the teeth. Other than the role of phosphorus in bone mineralization, it participates in numerous essential functions, especially in cell metabolism.

Pack size Box of 10 ampoules, 20 ampoules.
Shelf-life 24 months
Composition Magnesium gluconate, Calcium glycerophosphate
Dosage forms and strengths Oral solution: 10 ml (Magnesium gluconate 426 mg, Calcium glycerophosphate 456mg)
Product code :

PRESCRIBING INFORMATION

Indications:

Supplementation of calcium and magnesium in the following cases: patients in convalescence, in stress, elderly patients, menopausal women, children in growth.

Dosage:

  • Adults: 2 – 3 ampoules daily.
  • Children 6 to 15 years of age: 1 ampoule daily.

Do not take this medicine for more than 4 weeks

Usage:

Elnitine is administered orally, not injected. Take ampoule contents diluted in a little water at the start of a meal.

Known hypersensitivity to any ingredient of the drug.

Hypercalcaemia, hypercalciuria, calcium deposits in the tissues.

Patients who are on a fructose-free diet (because this drug contains sorbitol).

Children below 6 years of age.

This drug can, in certain persons, have unpleasant side effects which cause a greater or lesser degree of discomfort.

  • Hypermagnesaemia is uncommon after oral magnesium salts except in the presence of renal impairment. Other symptoms of hypermagnesaemia may include: nausea, vomiting, flushing of the skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, slurred speech, double vision, muscle weakness, bradycardia, coma, and cardiac arrest. Ingestion of magnesium salts may cause gastrointestinal irritation and hyperosmotic diarrhea.
  • Oral calcium salts can cause gastrointestinal irritation. Excessive amounts of calcium salts may lead to hypercalcaemia usually in patients with renal failure or who are also taking vitamin D. Symptoms of hypercalcaemia include: anorexia, nausea, vomiting, constipation, abdominal pain, muscle weakness, psychotic disturbances, polydipsia, polyuria, nephrocalcinosis, renal calculi, in severe cases, cardiac arrhythmias and coma can occur.

As containing sorbitol, this drug should be taken with caution in patients with obstruction of the bile ducts or severe liver disease.

If the patient is a diabetic or is on a low carbohydrate diet, take account of the fact that this preparation contains sucrose 2.5 g.

Take account of the fact that each ampoule contains 87.3 mg of calcium and 67 mg of phosphorus.

Oral magnesium salts should be used cautiously in patients with renal impairment.

Oral magnesium salts are taken with food may decrease the incidence of diarrhoea. Chronic diarrhoea from long-term use may result in electrolyte imbalance.

Calcium salts should be given cautiously to patients with renal impairment, or diseases associated with hypercalcaemia such as sarcoidosis and some malignancies. In addition, they should generally be avoided in patients with calcium renal calculi, or a history of renal calculi. Plasma-calcium concentrations should be monitored closely in patients with renal impairment and if large doses of vitamin D are used concurrently.

Elnitine contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Elnitine contains sorbitol. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product.

Elnitine contains sodium methyl p-hydroxybenzoate (sodium methyl paraben), which may cause allergic reactions (possibly delayed).